Coya Therapeutics, Inc. (COYA) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-04-09

Coya Therapeutics, Inc. (COYA) — no SEC Form 4 insider filings recorded in the last 90 days. 3 Form 8-K material event filings were reported by COYA in the last 90 days. InsiderAlpha tracks every COYA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Coya Therapeutics, Inc. (COYA)

SEC CIK	0001835022

90-Day SEC Filing Activity

Form 8-K filings (90d)	3
Latest Form 4 filing	2026-04-09

Recent COYA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-08-18	GOLDSTEIN DOV A MD	Director	M — Option exercise	17.6K	$1.09	$19K	SEC
2024-11-14	SNYDER DAVID S	Chief Financial Officer	P — Open-market purchase	1.8K	$7.19	$13K	SEC
2024-11-13	Swaminathan Arun	Chief Executive Officer	P — Open-market purchase	5.0K	$7.36	$37K	SEC
2024-11-11	Swaminathan Arun	Chief Executive Officer	P — Open-market purchase	5.0K	$7.34	$37K	SEC
2024-11-11	Grossman Fred	Chief Medical Officer	P — Open-market purchase	2.7K	$7.37	$20K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Coya Therapeutics, Inc. (COYA). Updated in real time as new filings are submitted to the SEC.

Recent COYA Form 8-K Material Events

2026-06-25 — Item 5.07 [SEC]
2026-05-12 — Item 1.01, 9.01 [SEC]
2026-05-12 — Item 2.02, 8.01, 9.01 [SEC]
2026-04-02 — Item 5.02, 9.01 · Leadership · negative [SEC]
Dr. Howard Berman resigned from the board of directors and his position as Executive Chairman of Coya Therapeutics, effective April 1, 2026. The company entered into a separation agreement providing prorated bonus, COBRA premium coverage through March 2027, and extended vesting/e
2026-03-16 — Item 2.02, 9.01 · Earnings · neutral [SEC]
Coya Therapeutics issued a press release on March 16, 2026 disclosing results of operations for fiscal year ended December 31, 2025. The filing provides standard financial results without indication of beat, miss, or material guidance changes.

Recent Insider Filings

2026-04-09 — Pavao Mark H (Insider)
2026-01-26 — SNYDER DAVID S (Chief Financial Officer)
2026-01-26 — Grossman Fred (Chief Medical Officer)
2026-01-26 — Berman Howard (Executive Chairman)
2026-01-26 — Swaminathan Arun (Chief Executive Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in COYA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

COYA Insider Trading — FAQ

What is the latest insider trade for COYA?: Coya Therapeutics, Inc. (COYA) had 0 insider filings in the last 90 days, with the most recent on 2026-04-09. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying COYA stock?: 0 insider purchases of COYA were filed in the last 90 days.
How many insiders are selling COYA stock?: 0 insider sales of COYA were filed in the last 90 days.
Where can I see COYA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every COYA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live COYA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.